Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $40.5 million.

  • Lineage Cell Therapeutics' Cash & Equivalents rose 45.81% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 45.81%. This contributed to the annual value of $45.8 million for FY2024, which is 29.19% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Cash & Equivalents of $40.5 million as of Q3 2025, which was down 4.28% from $42.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Cash & Equivalents' 5-year high stood at $78.1 million during Q1 2022, with a 5-year trough of $15.5 million in Q1 2023.
  • For the 3-year period, Lineage Cell Therapeutics' Cash & Equivalents averaged around $35.8 million, with its median value being $35.4 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 471.70% in 2021, then slumped by 80.21% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash & Equivalents (Quarterly) stood at $55.7 million in 2021, then decreased by 9.19% to $50.6 million in 2022, then fell by 29.99% to $35.4 million in 2023, then grew by 29.19% to $45.8 million in 2024, then skyrocketed by 45.81% to $40.5 million in 2025.
  • Its Cash & Equivalents was $40.5 million in Q3 2025, compared to $42.3 million in Q2 2025 and $47.9 million in Q1 2025.